More Articles Back to Article
Daewoong to advance Phase 1 study for COVID-19 drug
Daewoong Pharmaceutical of South Korea has gained regulatory approval to advance an early-stage trial for niclosamide, its anti-parasitic drug, to treat patients with COVID-19 infections. The company is aiming for conditional approval of DWRX2003, an antiviral drug, for emergency use after results become available from a midstage trial. Reuters (10/12)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!